质子束治疗后肝细胞癌局部复发的指标:对比增强CT上受照肿瘤与肝实质的衰减差分析
该回顾性研究纳入接受质子束治疗的肝细胞癌患者,比较复发与未复发病灶在增强CT门静脉期中受照肿瘤与受照肝实质的衰减差(ADHCC-IP)。复发灶在治疗后1–2年门静脉期的ADHCC-IP均值高于未复发灶,ADHCC-IP低于-55 HU与≥-55 HU的5年局部肿瘤控制率分别为0.93和0.56,提示该衰减差可预测长期局部复发。
要点
- 质子束治疗后1–2年门静脉期测量受照肿瘤与受照肝实质的衰减差,复发灶均值高于未复发灶。
- ADHCC-IP低于-55 HU的病灶5年局部肿瘤控制率为0.93,≥-55 HU者为0.56。
- 该衰减差可用于预测质子束治疗后肝细胞癌的长期局部复发。
核心结论
- 质子束治疗后1–2年门静脉期受照肝细胞癌与受照肝实质的衰减差可预测治疗后的长期局部复发。
- 作者识别出质子束治疗后肝细胞癌对比增强的截断值,可用于预测未来局部复发。
研究设计与样本
- 回顾性研究,检索2004年1月至2016年12月期间接受质子束治疗的肝细胞癌患者的CT扫描。
- 共纳入17个复发病灶和34个未复发病灶。
- 采用Mann-Whitney U检验比较两组受照肿瘤与受照肝实质的衰减差(ADHCC-IP),并用Youden指数估算截断值。
关键影像表现/征象
- 复发灶在质子束治疗后1–2年门静脉期的ADHCC-IP均值为-21.8 HU(范围-95至-31 HU),未复发灶均值为-51.7 HU(范围-117至-12 HU),复发灶显著大于未复发灶(p=0.039)。
- 复发灶随访时间374至2402天(中位1069天),未复发灶418至2923天(中位1091.5天),两组比较p=0.892。
- 质子束治疗后至局部复发出现的时间为189至2270天(中位497天)。
诊断标准与关键数值
- 以Youden指数估算的ADHCC-IP截断值为-55 HU,用于区分复发与未复发。
- ADHCC-IP在1–2年门静脉期低于-55 HU的病灶5年局部肿瘤控制率为0.93,≥-55 HU者为0.56。
临床应用与阅片要点
- 在质子束治疗后1–2年的门静脉期CT上,测量受照肿瘤与受照肝实质的衰减差有助于预测局部复发。
- ADHCC-IP≥-55 HU的病灶5年局部肿瘤控制率较低(0.56),ADHCC-IP低于-55 HU者较高(0.93)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to identify dynamic CT features that can be used for prediction of local recurrence of hepatocellular carcinoma (HCC) after proton beam therapy (PBT).
METHODS: We retrospectively retrieved CT scans of patients with PBT-treated HCC, taken between January 2004 and December 2016. 17 recurrent lesions and 34 non-recurrent lesions were retrieved. The attenuation difference between irradiated tumor and irradiated parenchyma (ADHCC-IP) was compared in the two groups by using the Mann-Whitney U test. Cut-off value of ADHCC-IP was estimated by using the Youden index.
RESULTS: The follow-up time after PBT initiation ranged from 374 to 2402 days (median, 1069 days) in recurrent lesions, and 418 to 2923 days (median, 1091.5 days) in non-recurrent lesions (p = 0.892). The time until appearance of local recurrence after PBT initiation ranged from 189 to 2270 days (median, 497 days). ADHCC-IP of recurrent lesions [mean, -21.8 Hounsfield units (HU); from -95 to -31 HU] was significantly greater than that of non-recurrent lesions (mean, -51.7 HU; from -117 to -12 HU) at 1-2 years in portal venous phase (p = 0.039). 5-year local tumor control rates were 0.93 and 0.56 in lesions with ADHCC-IP at 1-2 years in PVP < -55 and ≥ -55 HU, respectively.
CONCLUSION: The attenuation difference between irradiated HCC and irradiated liver parenchyma in portal venous phase at 1-2 years after PBT can predict long-term local recurrence of HCC after treatment.
ADVANCES IN KNOWLEDGE: We identified a cut-off value for contrast enhancement of HCC after PBT that could predict future local recurrence.
引用
- Takahashi H, Sekino Y, Mori K, et al. Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. Br J Radiol. 2019. PMID: 31670572. doi:10.1259/bjr.20190375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。